Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Alltest Biotech CoSHSE:688606 +1.19%53 EV-to-FCF is 201.51 as of Jul. 28, 2026, which is 6708% above its 10-year median of 2.96. GuruFocus rates SHSE:688606 with a GF Score™ of 53/100 and a GF Value™ of ¥85.74 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 415 Medical Devices & Instruments companies, Hangzhou Alltest Biotech Co ranks worse than 93.01% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hangzhou Alltest Biotech Co's Enterprise Value is ¥1,176.4 Mil.
Hangzhou Alltest Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥5.8 Mil. Therefore, Hangzhou Alltest Biotech Co's EV-to-FCF for today is 201.51.
The historical rank and industry rank for Hangzhou Alltest Biotech Co's EV-to-FCF or its related term are showing as below:
SHSE:688606'
s EV-to-FCF Range Over the Past 10 Years
Min: -252.84 Med: 2.96 Max: 471.47
Current: 208.44
During the past 10 years, the highest EV-to-FCF of Hangzhou Alltest Biotech Co was 471.47. The lowest was -252.84. And the median was 2.96.
SHSE:688606's EV-to-FCF is ranked worse than 93.01% of 415
companies
in the Medical Devices & Instruments industry
Industry Median: 23.08
vs SHSE:688606: 208.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hangzhou Alltest Biotech Co (SHSE:688606) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hangzhou Alltest Biotech Co's PE Ratio (TTM) for today is calculated as:
Hangzhou Alltest Biotech Co's share price for today is ¥43.47.
Hangzhou Alltest Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2.250.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hangzhou Alltest Biotech Co EV-to-FCF Related Terms
Hangzhou Alltest Biotech Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688606 vs ISRG, BDX, MDLN: EV-to-FCF Comparison
For the Medical Instruments & Supplies subindustry, Hangzhou Alltest Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Alltest Biotech Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou Alltest Biotech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hangzhou Alltest Biotech Co's EV-to-FCF falls into.
Hangzhou Alltest Biotech Co's current Enterprise Value is ¥1,176.4 Mil.
Hangzhou Alltest Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥5.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Alltest Biotech Co (SHSE:688606) has a EV-to-FCF of 201.51 as of Jul. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hangzhou Alltest Biotech Co and its competitors. This is 6708% above median its historical median of 2.96. According to the industry distribution chart, Hangzhou Alltest Biotech Co ranks #386 out of 415 companies in the Medical Devices & Instruments industry, placing it in the top 93%.
Is Hangzhou Alltest Biotech Co's EV-to-FCF too high?
Hangzhou Alltest Biotech Co's current EV-to-FCF of 201.51 is 6708% above median its 10-year median of 2.96. The Medical Devices & Instruments industry median EV-to-FCF is 23.08. Hangzhou Alltest Biotech Co's value of 201.51 is 773.1% above this industry median. Based on the distribution chart, Hangzhou Alltest Biotech Co ranks #386 out of 415 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Hangzhou Alltest Biotech Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Alltest Biotech Co's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou Alltest Biotech Co ranks #386 out of 415 companies for EV-to-FCF. This places Hangzhou Alltest Biotech Co in the lower half of its industry. The industry median EV-to-FCF is 23.08. Hangzhou Alltest Biotech Co's value of 201.51 is 773.1% above this benchmark. While the company's 10-year median is 2.96 vs. the industry median of 23.08, Hangzhou Alltest Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.08, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Alltest Biotech Co's current EV-to-FCF of 201.51 is 773.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hangzhou Alltest Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Alltest Biotech Co's current EV-to-FCF is 201.51, which is 6708% above median its own 10-year median of 2.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Alltest Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co (SHSE:688606) is currently considered Possible Value Trap. The stock's GF Value™ is ¥85.74, compared to a current price of ¥43.47 — trading 49.3% below its estimated fair value. The current EV-to-FCF is 201.51, which is 6708% above median its 10-year median of 2.96 and 773.1% above the Medical Devices & Instruments industry median of 23.08. Hangzhou Alltest Biotech Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hangzhou Alltest Biotech Co (SHSE:688606), the current EV-to-FCF is 201.51 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Alltest Biotech Co (SHSE:688606) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co stock appears to be undervalued.
The current stock price of ¥43.47 is trading 49.3% below its estimated GF Value™ of ¥85.74.
GuruFocus considers Hangzhou Alltest Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688606:
EV-to-FCF: 201.51 (6708% above median its 10-year median of 2.96)
GF Value™: ¥85.74 vs. price of ¥43.47 (49.3% below fair value)
Industry Position: 773.1% above the Medical Devices & Instruments median (#386 of 415)
No single metric tells the full story. See the SHSE:688606 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688606 has been successfully added to your 
